Filing Analysis

💸 Securities Offering Filed Aug 01, 2024
🟡 MEDIUM

Cyberloq Technologies, Inc. has obtained shareholder approval to increase its authorized common stock from 200 million to 300 million shares. The expansion is intended to facilitate capital raises of up to $3,000,000 through the end of 2025 to fund operations and software development.

🚩 Red Flags

  • Significant dilution risk: The 50% increase in authorized shares provides the company with substantial capacity to issue new equity, which typically dilutes existing shareholders.
  • Capital necessity: The explicit stated need to raise funds just to cover 'expenses moving forward' and fund software development suggests limited cash runway.

📋 Key Facts

  • Shareholders approved an amendment to Articles of Incorporation via written consent on July 31, 2024.
  • Authorized common stock increased from 200,000,000 to 300,000,000 shares.
  • The company intends to raise up to $3,000,000 through future private placements or public offerings.
  • Funds are earmarked for operational expenses and upgrading Cyberloq source code/infrastructure.
📄 Other SEC Filing Filed Feb 15, 2024
⚪ LOW

The Company reports that a lawsuit filed by Mark Carten against Cyberloq Technologies, Inc. (UNN-L-3456-22) has been dismissed without prejudice by the Superior Court of New Jersey as of February 13, 2024.

📋 Key Facts

  • Litigation matter: Mark Carten v. Cyberloq Technologies, Inc. (UNN-L-3456-22).
  • Court: Superior Court of New Jersey.
  • Outcome: Dismissed without prejudice on February 13, 2024.
  • Status: The litigation is no longer pending.
Disclaimer: This analysis is generated by AI and is for informational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities. Always review the original SEC filings and consult a financial advisor before making investment decisions.

Get real-time alerts for CLOQ

Subscribers receive AI-powered analysis within minutes of new SEC filings — not days later.

Start 14-Day Free Trial